Crucial Role of AIM/CD5L in the Development of Glomerular Inflammation in IgA Nephropathy

A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy

(2019) James R. Myette et al.   KIDNEY INTERNATIONAL

Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1

(2019) Dana V. Rizk et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The IgM pentamer is an asymmetric pentagon with an open groove that binds the AIM protein

(2018) Emiri Hiramoto et al.   Science Advances

Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice

(2016) Satoko Arai et al.   NATURE MEDICINE

Impact of feline AIM on the susceptibility of cats to renal disease

(2016) Ryoichi Sugisawa et al.   Scientific Reports

Pathogenic Role of a Proliferation-Inducing Ligand (APRIL) in Murine IgA Nephropathy

(2015) Yang Gyun Kim et al.   PLoS One

IgA nephropathy: association of C4d with clinical and histopathological findings and possible role of IgM

(2015) Cihan Heybeli et al.   RENAL FAILURE

Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy

(2014) Yusuke Suzuki et al.   Clinical and Experimental Nephrology

Circulating AIM Prevents Hepatocellular Carcinoma through Complement Activation

(2014) Natsumi Maehara et al.   Cell Reports

Obesity-Associated Autoantibody Production Requires AIM to Retain the Immunoglobulin M Immune Complex on Follicular Dendritic Cells

(2013) Satoko Arai et al.   Cell Reports

Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy

(2012) Yukihiro Wada et al.   Clinical and Experimental Nephrology

Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy

(2012) T. Matthew Eison et al.   CLINICAL NEPHROLOGY

Development of a Model of Early-Onset IgA Nephropathy

(2012) K. Okazaki et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Autoantibodies Targeting Galactose-Deficient IgA1 Associate with Progression of IgA Nephropathy

(2012) F. Berthoux et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Activated innate immunity and the involvement of CX3CR1–fractalkine in promoting hematuria in patients with IgA nephropathy

(2012) Sharon N. Cox et al.   KIDNEY INTERNATIONAL

A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity

(2012) M. Jinek et al.   SCIENCE

AIMing at Metabolic Syndrome

(2011) Toru Miyazaki et al.   CIRCULATION JOURNAL

The Pathophysiology of IgA Nephropathy

(2011) H. Suzuki et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort

(2011) S. S. Bellur et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Apoptosis inhibitor of macrophage (AIM) is required for obesity-associated recruitment of inflammatory macrophages into adipose tissue

(2011) J. Kurokawa et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Macrophage-Derived AIM Is Endocytosed into Adipocytes and Decreases Lipid Droplets via Inhibition of Fatty Acid Synthase Activity

(2010) Jun Kurokawa et al.   Cell Metabolism

IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1

(2008) Hitoshi Suzuki et al.   JOURNAL OF CLINICAL INVESTIGATION